
Sign up to save your podcasts
Or


Dr Joyce O’Shaughnessy from Sarah Cannon Research Institute in Dallas, Texas, Dr Mark D Pegram from Stanford Cancer Institute in California, and Prof Peter Schmid from Barts Cancer Institute in London, United Kingdom, summarize currently available data guiding treatment decision-making for patients with low and ultralow HER2 expression and present cases from their practices.
CME information and select publications here.
By Dr. Neil Love4.4
6262 ratings
Dr Joyce O’Shaughnessy from Sarah Cannon Research Institute in Dallas, Texas, Dr Mark D Pegram from Stanford Cancer Institute in California, and Prof Peter Schmid from Barts Cancer Institute in London, United Kingdom, summarize currently available data guiding treatment decision-making for patients with low and ultralow HER2 expression and present cases from their practices.
CME information and select publications here.

138 Listeners

323 Listeners

498 Listeners

30 Listeners

76 Listeners

14 Listeners

17 Listeners

12 Listeners

0 Listeners

121 Listeners

57 Listeners

294 Listeners

3,361 Listeners

205 Listeners

515 Listeners

59 Listeners

193 Listeners

0 Listeners